Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists
- Authors
- Park Kawngwoo; Park Kwang Hyon; Park Hye Ran; Lee Jae Meen; Kim Yong Hwy; Kim Dong-Young; Won Tae-Bin; Kong Sung Hye; Kim Jung Hee; Shin Chan Soo; Paek Sun Ha
- Issue Date
- Apr-2021
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Pituitary Surgery; Prolactinoma; Dopamine Agonist; Microscopic Transsphenoidal Surgery
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.36, no.15, pp.1 - 10
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 36
- Number
- 15
- Start Page
- 1
- End Page
- 10
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81069
- DOI
- 10.3346/jkms.2021.36.e97
- ISSN
- 1011-8934
- Abstract
- Background: Although long-term dopamine agonist (DA) therapy is recommended as a first-line treatment for prolactinoma, some patients may prefer surgical treatment because of the potential adverse effects of long-term medication, or the desire to become pregnant. This study aimed to determine whether surgical treatment of prolactinomas could be an alternative to DA therapy.
Methods: In this retrospective study, 96 consecutive patients (74 female, 22 male) underwent primary pituitary surgery without long-term DA treatment for prolactinomas at a single institution from 1990 to 2010. All patients underwent primary surgical treatment in the microscopic transsphenoidal approach (TSA).
Results: The median age and median follow-up period were 31 (16–73) years and 139.1 (12.2–319.6) months, respectively. An initial overall remission was accomplished in 47.9% (46 of 96 patients, 33 macroadenomas, and 13 microadenomas) of patients. DA dose reduction was achieved in all patients after TSA. A better remission rate was independently predicted by lower diagnostic prolactin levels and by a greater extent of surgical resection. Overall remission at the last follow-up was 33.3%, and the overall recurrence rate was 30.4%. The permanent complication rate was 3.1%, and there was no mortality.
Conclusion: TSA can be considered a safe and potentially curative treatment for selective microprolactinomas as an alternative to treatment with a long-term DA.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.